• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >Remdesivir and Coronavirus Disease 2019 (COVID-19): Essential Questions and Answers for Pharmacists and Pharmacy Technicians
【24h】

Remdesivir and Coronavirus Disease 2019 (COVID-19): Essential Questions and Answers for Pharmacists and Pharmacy Technicians

机译：Remdesivir和Coronavirus疾病2019（Covid-19）：药剂师和药房技术人员的基本问题和答案

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To conduct a review of the investigational drug remdesivir and its therapeutic potential for treatment of COVID-19, in the form of a series of questions and answers. The purpose of the review is to narrow gaps in knowledge, clarify concepts, and to investigate research advancements for health care professionals. Data Sources: From June 2020 to August 2020, we conducted comprehensive searches of MEDLINE-PubMed, Scopus, and Google Scholar databases with no time limitations. Search terms were included that contained the terms “remdesivir,” “COVID-19,” “novel coronavirus” and “evidence,” “therapy,” “safety,” “effectiveness,” “efficacy,” “clinical trial.” Study Selection and Data Extraction: The sources of information include all publicly available data from previously published research reports. Reports must have at least one reference to remdesivir as a treatment modality for COVID-19 with no specified outcomes. Data Synthesis: Major research findings on the efficacy and safety of remdesivir are summarized in tabular format and presented in chronological order. Results of this review reveal remdesivir to be an effective therapy in specific clinical contexts; however, in several areas, available data are insufficient to support evidence-based guidance for remdesivir in the treatment of COVID-19. Conclusions: Clinical trials on remdesivir are ongoing, yet questions remain and further research is needed as to the selection of patients, effectiveness, and duration of treatment in the use of remdesivir for treatment of COVID-19.
机译：目的：通过2019冠状病毒疾病的研究，以一系列问答形式对药物ReDeViVi及其治疗潜力进行综述。审查的目的是缩小知识差距，澄清概念，并调查卫生保健专业人员的研究进展。数据来源：从2020年6月到2020年8月，我们对MEDLINE PubMed、Scopus和Google Scholar数据库进行了全面搜索，没有时间限制。新型冠状病毒包括“Re2019冠状病毒疾病”、“COVID-19”、“新型冠状病毒”和“证据”、“治疗”、“安全性”、“有效性”、“疗效”、“临床试验”。研究选择和数据提取：信息来源包括以前发表的研究报告中的所有公开数据。2019冠状病毒疾病的治疗方式至少有一个参考，而没有明确的结果。数据综合：关于雷德西韦疗效和安全性的主要研究结果以表格形式总结，并按时间顺序呈现。这篇综述的结果显示，雷姆德西韦在特定的临床环境中是一种有效的治疗方法；然而，在2019冠状病毒疾病治疗中，有几个数据是不足以支持ReDeViVe的循证指导。2019冠状病毒疾病的临床试验正在进行中，但仍有待进一步的研究，需要进一步研究，以选择使用ReimDVIL治疗COVID-19患者的疗效、有效性和持续时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号